AZTA — Azenta, Inc.
Is AZTA overbought or oversold? Here is the current MarketMoodz read.
Azenta, Inc. (AZTA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $45.81. The rating moved from Neutral to Overbought on November 17, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$45.81
- Last changeMoved from Neutral to Overbought on November 17, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all overbought Healthcare stocks →
AI analysis
Azenta is well positioned in sample management and genomic workflows with a recurring consumables and services revenue base that benefits from growth in biopharma, specialty distribution and automated lab solutions. Near-term industry tailwinds around specialty therapies and increased outsourcing support stable demand, while operating leverage and targeted M&A could drive margin expansion. Key challenges include customer concentration, R&D spend cyclicality, competitive pressure from larger OEMs and execution risk on integrations. With current market calm and selective support for growth exposures, the company’s fundamentals suggest positive catalysts over the coming weeks if execution and order momentum hold.
Key factors
- Market position in sample management, cold-chain logistics and genomic workflow automation provides recurring consumables and services revenue.
- Exposure to growing biopharma and specialty care distribution channels aligned with increased demand for biologics, cell & gene therapy and chronic injectable therapies.
- Defensive industry flows into large-cap pharma and specialty franchises create downstream demand for service and distribution partners.
- Recurring revenue mix and after‑sales consumables increase revenue visibility and margin resilience versus one‑time equipment sales.
- Opportunities for margin expansion via operating leverage and integration of add-on acquisitions in adjacent service capabilities.
- Relatively muted macro volatility in the near term supports capital spending continuity among customers.
Risks
- Customer concentration risk: large biopharma accounts can materially influence revenue if procurement patterns change.
- Cyclicality in R&D and capital spending by pharmaceutical and academic customers could slow equipment orders in a downturn.
- Competition from larger life‑science tools and logistics providers may pressure pricing and share gains.
- Supply‑chain disruptions or component shortages that delay installations and consumables shipments.
- Integration execution risk for M&A-driven growth initiatives and potential dilution from acquisitions.
- Regulatory or compliance issues in sample handling, cold‑chain logistics or laboratory services that increase costs or restrict operations.
See today's live rating, score and targets
Members see the live hourly rating for AZTA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.